Skip to main
  1. Stocks
  2. Becton, Dickinson and Co.
  3. Forecast
BDX

BDX Stock Forecast & Price Target

BDX Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 33%
Buy 20%
Hold 40%
Sell 7%
Strong Sell 0%

Bulls say

Becton Dickinson is positioned favorably because its post-separation portfolio is now a more focused pure-play MedTech platform, with Medical Essentials, Connected Care, Biopharma Systems, and Interventional supported by a durable U.S.-centric base and more than 60% of revenue from the United States. The company’s outlook is strengthened by recurring demand, a +90% consumables revenue mix, and exposure to a $70B TAM growing at about 5%, while BD Excellence should keep lifting productivity, quality, and margins toward ~30% over time. Additional upside comes from the $18B Waters-related transaction, ~39% ownership, ~$345MM of annualized EBITDA synergies, and disciplined capital allocation, including ~$4B in cash proceeds, FY25 shareholder returns of about $2.2B, and buybacks as the top priority.

Bears say

Becton Dickinson is facing a weaker fundamental setup as the separation-driven “new BD” must still prove it can sustain growth while absorbing business investments, tariff pressure, and potential M&A dilution, even after benefits from BD Excellence. China remains a significant risk, with accelerating headwinds from VBP and the possibility that ongoing pressures could extend into FY26, while Alaris is expected to become a 200bp organic growth headwind in FY27 and create roughly 60bp of margin pressure as sales fall from about $500M to $100M. Although FQ4 revenue rose to $5,274M and EPS reached $4.15, the stock’s 16x NTM P/E looks demanding for a low-to-mid single-digit grower with limited pricing power and heavy U.S. concentration, making the downside case more compelling.

BDX has been analyzed by 15 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 20% recommend Buy, 40% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Becton, Dickinson and Co. and is not a guaranteed prediction by Public.com or investment advice.

BDX Analyst Forecast & Price Prediction

Get the latest BDX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in BDX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Becton, Dickinson and Co. (BDX) Forecast

Analysts have given BDX a Buy based on their latest research and market trends.

According to 15 analysts, BDX has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $204.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $204.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Becton, Dickinson and Co. (BDX)


BDX Analyst Forecast & Price Prediction

Get the latest BDX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in BDX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover BDX stock data and trends